Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Immunology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Amyloidosis Clinical Trials

A listing of Amyloidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (11) clinical trials

A Phase 1/2 Study of CYT-0851 an Oral RAD51 Inhibitor in B-Cell Malignancies and Advanced Solid Tumors

Overexpression of activation-induced cytidine deaminase (AID) or other cytidine deaminases causes high rates of deoxyribonucleic acid (DNA) damage (mutations, double strand DNA breaks, and chromosome rearrangements) in a high number of patients with B-cell malignancies, such as NHL, MM, and CLL, and in a subset of patients with solid tumors, ...

Phase

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Study phase: phase III Study objective: Comparison of Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed autologous stem cell transplantation (ASCT) Comparison of Bortezomib, Lenalidomide, Dexamethasone(VRD) as consolidation versus no consolidation Comparison of single versus tandem high dose Melphalan with ASCT Patient population: Patients with symptomatic multiple myeloma,previously untreated, ...

Phase

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

All patients will be randomized in a 1:1 ratio to receive: ARM A: Bortezomib (V): 1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4; 1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 in cycles 5-9. Melphalan (M): 9 mg/m2 orally ...

Phase

A Study of Daratumumab Carfilzomib Lenalidomide and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenalidomide, bortexomib, and dexamethasone (VRD).

Phase

A Study of WVT078 in Patients With Multiple Myeloma (MM)

This first-in-human trial with WVT078 is a dose escalation study whose primary purpose is to characterize the safety, tolerability, and determine recommended dose regimen(s) of WVT078 in subjects with MM who have received two or more standard of care lines of therapy including an IMID, a proteasome inhibitor, and an ...

Phase

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Pulmonary sarcoidosis-associated pulmonary hypertension is classified as WHO Group 5 pulmonary hypertension and may occur in anywhere from 5-20% of sarcoidosis patients. Inhaled treprostinil has shown clinical improvements in exercise capacity after 12 weeks of therapy in patients with WHO Group 1 pulmonary hypertension. More recently, there has been interest ...

Phase

Efficacy of First Line B-RI for Treatment Naive Waldenstr m's Macroglobulinemia

In Waldenstrm's macroglobulinemia (WM) conventional chemotherapy induces only low complete remission (CR) rates and responses of short duration compared to other indolent lymphomas. Thus innovative approaches are needed which combine excellent activity and tolerability in patients with WM, who are mostly of advanced age. Today, chemotherapy in combination with the ...

Phase

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

The purpose of this study is to evaluate the efficacy of ibrutinib based on overall response rate (ORR) (partial response [PR] or better) by investigator assessment per the modified Consensus Response Criteria from the Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (NCCN 2019), in Chinese participants with relapsed or refractory ...

Phase

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This is a dose de-escalation study of copanlisib. Patients receive copanlisib intravenously (IV) over 1 hour on days 1, 8, and 15 or days 1 and 15 (depending on dose level). Patients also receive rituximab IV on day 1 and bendamustine IV on days 1 and 2 of cycles 1-4. ...

Phase

Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.

Multiple Myeloma (MM) is a mature B-cell lymphoma characterized by monoclonal proliferation of tumor plasma cells invading the bone marrow. It is the second malignant hemopathy among Non-Hodgkin's Lymphomas. Etiology of the disease is poorly understood. Its higher incidence in black subjects suggests the existence of genetic factors. Numerous studies ...

Phase N/A